Research of a new small-molecule 1,2,4-triazine derivative (MM-129) - assessment of anti-neoplastic activity and safety of use in an experimental model of colorectal carcinoma.
2018/31/B/NZ7/00875
Keywords
Descriptors
- NZ7_14: Farmacja, farmakoterapia, farmakologia
Panel
NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution
Uniwersytet Medyczny w Białymstoku, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej
Voivodeship: podlaskie
Principal investigator (from the host institution)
Number of co-investigators in the project: 10
Call
OPUS 16 – announced on 2018-09-14
- Amount awarded
- 1 434 320 PLN
- Project start date
- 2019-06-28
- Project end date
- 2022-12-27
- Project duration
- 42 months (the same as in the proposal)
- Project status
- Project settled
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Equipment purchased [PL]
- Cyfrowa kolorowa kamera mikroskopowa. Cost: 80 000 PLN
- Inkubator CO2 z wyposażeniem. Cost: 60 000 PLN
- System do obrazowania żeli i blotów z zestawem do elektroforezy i transferu. Cost: 268 470 PLN
Information in the final report
Publication in academic press/journals (4)
-
Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer
- Authors:
- Justyna Magdalena Hermanowicz, Anna Szymanowska, Beata Sieklucka, Robert Czarnomysy, Krystyna Pawlak, Anna Bielawska, Krzysztof Bielawski, Joanna Kalafut, Alicja Przybyszewska, Arkadiusz Surazynski, Adolfo Rivero-Muller, Mariusz Mojzych, Dariusz Pawlak
- Academic press:
- Journal of Enzyme Inhibition and Medicinal Chemistry (year: 2021, volume: 36, pages: 535-348), Publisher: Taylor & Francis Group
- Status:
- Published
- DOI:
- 10.1080/14756366.2021.1879803 – link to the publication
-
MM-129 as a novel inhibitor targeting PI3K/AKT/mTOR and PD-L1 in colorectal cancer.
- Authors:
- ermanowicz Justyna Magdalena, Pawlak Krystyna, Sieklucka Beata, Czarnomysy Robert, Kwiatkowska Iwona, Kazberuk Adam, Surażyński Arkadiusz, Mojzych Mariusz, Pawlak Dariusz.
- Academic press:
- Cancers (year: 2021, volume: 13, pages: 3203), Publisher: MDPI
- Status:
- Published
- DOI:
- 10.3390/cancers13133203 – link to the publication
-
Important players in carcinogenesis as potential targets in cancer therapy: an update
- Authors:
- Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Dariusz Pawlak
- Academic press:
- Oncotarget (year: 2020, volume: 11, pages: 3078-3101), Publisher: eJournalPress
- Status:
- Published
- DOI:
- 10.18632/oncotarget.27689 – link to the publication
-
Preclinical toxicity and safety of MM-129 - first-in-class BTK/PD-L1 inhibitor as a potential candidate against colon cancer.
- Authors:
- Hermanowicz Justyna Magdalena, Kałaska Bartłomiej, Pawlak Krystyna, Sieklucka Beata, Mikłosz Joanna, Mojzych Mariusz, Pawlak Dariusz.
- Academic press:
- Pharmaceutics (year: 2021, volume: 13, pages: 1222), Publisher: MDPI
- Status:
- Published
- DOI:
- 10.3390/pharmaceutics13081222 – link to the publication
Articles in post-conference publications (6)
-
MM-129 as a new potential candidate against colon cancer - assessment of toxicity.
- Authors:
- Justyna Hermanowicz, Iwona Kwiatkowska, Dariusz Pawlak
- Conference:
- 10th Jubilee International Conference on Radiation in Various Fields of Research, Herceg Novi, Montenegro (year: 2022, pages: 33), Publisher: nie dotyczy
- Date:
- conference 13-17 czerwca
- Status:
- Published
-
MM-129: a derivative with a dual mechanism of action as an innovative molecule with antitumor activity against colon cancer cells.
- Authors:
- Iwona Kwiatkowska, Justyna Hermanowicz, Robert Czarnomysy, Arkadiusz Surażyński, Dariusz Pawlak
- Conference:
- 10th Jubilee International Conference on Radiation in Various Fields of Research, Herceg Novi, Montenegro (year: 2022, pages: 32), Publisher: nie dotyczy
- Date:
- conference 13-17 czerwca
- Status:
- Published
-
MM-129 as novel potential anticancer agent against colorectal cancer.
- Authors:
- Justyna Hermanowicz, Iwona Kwiatkowska, Arkadiusz Surażyński, Dariusz Pawlak
- Conference:
- ACCORD 2022. Interdisciplinary Conference on Drug Sciences Synergy of interdisciplinary innovations (year: 2022, pages: 65), Publisher: MDPI
- Date:
- conference 26-28 maj
- Status:
- Published
-
Evaluation of the anticancer activities of novel 1,2,4-triazine sulfonamide derivative in colon cancer.
- Authors:
- Justyna Hermanowicz, Arkadiusz Surażyński, Hubert Klepacki, Dariusz Pawlak.
- Conference:
- New Trends in Polish and Global Pharmacy: Science, Business, and Modern Education. Poznań (year: 2022, pages: 54), Publisher: nie dotyczy
- Date:
- conference 29-30 września
- Status:
- Published
-
Proapoptotic activity of MM-129 in experimental colon cancer models.
- Authors:
- Kwiatkowska Iwona, Hermanowicz Justyna, Czarnomysy Robert, Bielawska Anna, Mojzych Mariusz, Bielawski Krzysztof, Pawlak Dariusz.
- Conference:
- ACCORD 2022. Interdisciplinary Conference on Drug Sciences Synergy of interdisciplinary innovations. (year: 2022, pages: 178), Publisher: MDPI
- Date:
- conference 26-28 maj
- Status:
- Published
-
Synthesis and cellular effects of novel 1,2,4-triazine derivative in human colon cancer
- Authors:
- Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Krystyna Pawlak, Mariusz Mojzych, Anna Bielawska, Krzysztof Bielawski, Dariusz Pawlak
- Conference:
- X Konwersatorium Chemii Medycznej (year: 2021, pages: s. 74), Publisher: Polskie Towarzystwo Chemii Medycznej
- Date:
- conference 2021-09-3-5
- Status:
- Published